Compare PLX & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLX | ZSQR |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 204.6M |
| IPO Year | 1996 | 2020 |
| Metric | PLX | ZSQR |
|---|---|---|
| Price | $2.67 | $2.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 757.1K | 303.9K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.27 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | $1,363,045.00 |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $2.81 |
| 52 Week High | $3.19 | $16.62 |
| Indicator | PLX | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 32.20 |
| Support Level | $2.59 | N/A |
| Resistance Level | $2.71 | $4.38 |
| Average True Range (ATR) | 0.09 | 0.45 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 87.78 | 15.53 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.